Go Pro
→ Three companies about to leapfrog Nvidia [And transform the entire industry] (From Eagle Publishing) (Ad)tc pixel Free CNSL Stock Alerts

Cambridge Nutritional Sciences (CNSL) Competitors

GBX 1.30 -0.10 (-7.14%)
As of 09/11/2026 12:15 PM Eastern
Compare

CNSL vs. AVO, ODX, MHC, SUN, and BELL

Should you buy Cambridge Nutritional Sciences stock or one of its competitors? Cambridge Nutritional Sciences's main competitors and comparable companies include Advanced Oncotherapy (AVO), Omega Diagnostics Group (ODX), MyHealthChecked (MHC), Surgical Innovations Group (SUN), and Belluscura (BELL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Cambridge Nutritional Sciences compare to Advanced Oncotherapy?

Cambridge Nutritional Sciences (LON:CNSL) and Advanced Oncotherapy (LON:AVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Advanced Oncotherapy has a net margin of 0.00% compared to Cambridge Nutritional Sciences' net margin of -83.53%. Advanced Oncotherapy's return on equity of -67.34% beat Cambridge Nutritional Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences-83.53% -69.62% -2.36%
Advanced Oncotherapy N/A -67.34%-11.73%

1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are owned by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are owned by insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cambridge Nutritional Sciences had 3 more articles in the media than Advanced Oncotherapy. MarketBeat recorded 3 mentions for Cambridge Nutritional Sciences and 0 mentions for Advanced Oncotherapy. Cambridge Nutritional Sciences' average media sentiment score of 0.36 beat Advanced Oncotherapy's score of 0.00 indicating that Cambridge Nutritional Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
Advanced Oncotherapy Neutral

Cambridge Nutritional Sciences has higher revenue and earnings than Advanced Oncotherapy. Advanced Oncotherapy is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.38-£3.03M£0.602.17
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A

Cambridge Nutritional Sciences has a beta of 1.911, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Advanced Oncotherapy has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

Summary

Cambridge Nutritional Sciences beats Advanced Oncotherapy on 8 of the 12 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Omega Diagnostics Group?

Cambridge Nutritional Sciences (LON:CNSL) and Omega Diagnostics Group (LON:ODX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Cambridge Nutritional Sciences had 3 more articles in the media than Omega Diagnostics Group. MarketBeat recorded 3 mentions for Cambridge Nutritional Sciences and 0 mentions for Omega Diagnostics Group. Cambridge Nutritional Sciences' average media sentiment score of 0.36 beat Omega Diagnostics Group's score of 0.00 indicating that Cambridge Nutritional Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
Omega Diagnostics Group Neutral

Cambridge Nutritional Sciences has a beta of 1.911, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Omega Diagnostics Group has a beta of 3.85, suggesting that its share price is 285% more volatile than the broader market.

Cambridge Nutritional Sciences has higher revenue and earnings than Omega Diagnostics Group. Omega Diagnostics Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.38-£3.03M£0.602.17
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A

1.6% of Cambridge Nutritional Sciences shares are held by institutional investors. Comparatively, 29.8% of Omega Diagnostics Group shares are held by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are held by insiders. Comparatively, 50.6% of Omega Diagnostics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Omega Diagnostics Group has a net margin of -51.15% compared to Cambridge Nutritional Sciences' net margin of -83.53%. Omega Diagnostics Group's return on equity of -29.14% beat Cambridge Nutritional Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences-83.53% -69.62% -2.36%
Omega Diagnostics Group -51.15%-29.14%-10.53%

Summary

Cambridge Nutritional Sciences beats Omega Diagnostics Group on 7 of the 12 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to MyHealthChecked?

MyHealthChecked (LON:MHC) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

In the previous week, Cambridge Nutritional Sciences had 3 more articles in the media than MyHealthChecked. MarketBeat recorded 3 mentions for Cambridge Nutritional Sciences and 0 mentions for MyHealthChecked. Cambridge Nutritional Sciences' average media sentiment score of 0.36 beat MyHealthChecked's score of 0.00 indicating that Cambridge Nutritional Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
MyHealthChecked Neutral
Cambridge Nutritional Sciences Neutral

MyHealthChecked has a net margin of -49.51% compared to Cambridge Nutritional Sciences' net margin of -83.53%. MyHealthChecked's return on equity of -22.78% beat Cambridge Nutritional Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
MyHealthChecked-49.51% -22.78% -8.18%
Cambridge Nutritional Sciences -83.53%-69.62%-2.36%

MyHealthChecked has higher earnings, but lower revenue than Cambridge Nutritional Sciences. MyHealthChecked is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MyHealthChecked£3.22M1.48-£1.04M-£3.76N/A
Cambridge Nutritional Sciences£8.06M0.38-£3.03M£0.602.17

MyHealthChecked has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 1.911, indicating that its share price is 91% more volatile than the broader market.

0.7% of MyHealthChecked shares are owned by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. 9.3% of MyHealthChecked shares are owned by company insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Cambridge Nutritional Sciences beats MyHealthChecked on 8 of the 13 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Surgical Innovations Group?

Surgical Innovations Group (LON:SUN) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Surgical Innovations Group has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 1.911, meaning that its share price is 91% more volatile than the broader market.

In the previous week, Cambridge Nutritional Sciences had 3 more articles in the media than Surgical Innovations Group. MarketBeat recorded 3 mentions for Cambridge Nutritional Sciences and 0 mentions for Surgical Innovations Group. Cambridge Nutritional Sciences' average media sentiment score of 0.36 beat Surgical Innovations Group's score of 0.00 indicating that Cambridge Nutritional Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Surgical Innovations Group Neutral
Cambridge Nutritional Sciences Neutral

2.8% of Surgical Innovations Group shares are owned by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. 22.2% of Surgical Innovations Group shares are owned by insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Surgical Innovations Group has higher revenue and earnings than Cambridge Nutritional Sciences. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgical Innovations Group£11.60M0.32N/A-£0.10N/A
Cambridge Nutritional Sciences£8.06M0.38-£3.03M£0.602.17

Surgical Innovations Group has a net margin of -4.96% compared to Cambridge Nutritional Sciences' net margin of -83.53%. Surgical Innovations Group's return on equity of -6.04% beat Cambridge Nutritional Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Surgical Innovations Group-4.96% -6.04% -3.03%
Cambridge Nutritional Sciences -83.53%-69.62%-2.36%

Summary

Cambridge Nutritional Sciences beats Surgical Innovations Group on 7 of the 12 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Belluscura?

Belluscura (LON:BELL) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Cambridge Nutritional Sciences has a net margin of -83.53% compared to Belluscura's net margin of -2,243.45%. Cambridge Nutritional Sciences' return on equity of -69.62% beat Belluscura's return on equity.

Company Net Margins Return on Equity Return on Assets
Belluscura-2,243.45% -97.35% -43.53%
Cambridge Nutritional Sciences -83.53%-69.62%-2.36%

Belluscura has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 1.911, indicating that its share price is 91% more volatile than the broader market.

0.2% of Belluscura shares are owned by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. 7.1% of Belluscura shares are owned by insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cambridge Nutritional Sciences has higher revenue and earnings than Belluscura. Belluscura is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Belluscura£1.80M1.67-£29.55M-£13.10N/A
Cambridge Nutritional Sciences£8.06M0.38-£3.03M£0.602.17

In the previous week, Cambridge Nutritional Sciences had 3 more articles in the media than Belluscura. MarketBeat recorded 3 mentions for Cambridge Nutritional Sciences and 0 mentions for Belluscura. Cambridge Nutritional Sciences' average media sentiment score of 0.36 beat Belluscura's score of 0.00 indicating that Cambridge Nutritional Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Belluscura Neutral
Cambridge Nutritional Sciences Neutral

Summary

Cambridge Nutritional Sciences beats Belluscura on 12 of the 13 factors compared between the two stocks.

Get Cambridge Nutritional Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNSL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNSL vs. The Competition

Export
MetricCambridge Nutritional SciencesHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£3.09M£5.44B£7.15B£2.87B
Dividend YieldN/A1.79%2.56%6.23%
P/E Ratio2.1725.09274.95366.83
Price / Sales0.3882.90656.5683,599.70
Price / CashN/A32.5377.0427.89
Price / Book0.335.9710.336.33
Net Income-£3.03M£150.75M£3.50B£5.89B
7 Day Performance-28.06%-2.83%-3.32%-0.69%
1 Month Performance-35.00%-3.09%-0.41%0.18%
1 Year Performance-57.24%9.34%19.21%20.03%

Cambridge Nutritional Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNSL
Cambridge Nutritional Sciences
N/AGBX 1.30
-7.1%		N/A-57.0%£3.09M£8.06M2.173,200
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/AN/A3,900
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55MN/A91
MHC
MyHealthChecked
N/AGBX 9.15
+1.7%		N/A-10.7%£4.76M£3.22MN/A16
SUN
Surgical Innovations Group
N/AGBX 0.40
-5.6%		N/A-45.0%£3.96M£11.60MN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CNSL) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
A major gold reset could be closer than people think
For 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...
Reagan Gold Group | Sponsoredtc pixel
17 Nobel Prize winners… one startling warning
On July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...
Porter & Company | Sponsoredtc pixel
your job is on the list
The CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...
Behind the Markets | Sponsoredtc pixel
I called NVDA at $6 - Here's what’s next…
Matt McCall called NVDA at 6 dollars - it's since climbed more than 3,100 percent. He's identified 51 stocks t...
Monument Traders Alliance | Sponsoredtc pixel